Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Imfinzi also recommended for patients with mismatch repair deficient disease
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Renews GMP certifications for India and Malaysia sites
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Subscribe To Our Newsletter & Stay Updated
